EGFR and lung adenocarcinoma: The study contains data on H3255, a lung adenocarcinoma cell line sensitive to EGFR-directed tyrosine kinase inhibitors, and H1975, another lung adenocarcinoma cell line resistant to first-generation reversible EGFR-TKIs, such as Erlotinib.